N-Demethyl Olanzapine (CAS 161696-76-0)
See product citations (4)
QUICK LINKS
N-Demethyl Olanzapine is a metabolite of Olanzapine, formed by the demethylation of the parent compound. It functions as a potent antagonist at multiple neurotransmitter receptors, including serotonin and dopamine receptors. This metabolite exerts its mode of action by binding to and blocking the activity of these receptors, thereby altering neurotransmission in the central nervous system. N-Demethyl Olanzapine acts as an antagonist at serotonin 5-HT2A and 5-HT2C receptors, as well as dopamine D1, D2, D3, and D4 receptors. This interaction with neurotransmitter receptors modulates the release and reuptake of various neurotransmitters, leading to its functional role in experimental applications. N-Demethyl Olanzapine′s mode of action at the molecular and cellular level involves the inhibition of specific receptor-mediated signaling pathways, contributing to its functional impact in development.
N-Demethyl Olanzapine (CAS 161696-76-0) References
- First experiences in combination therapy using olanzapine with SSRIs (citalopram, paroxetine) in delusional depression. | König, F., et al. 2001. Neuropsychobiology. 43: 170-4. PMID: 11287796
- Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. | Josefsson, M., et al. 2010. J Pharm Biomed Anal. 53: 576-82. PMID: 20452161
- The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. | Haslemo, T., et al. 2011. Br J Clin Pharmacol. 71: 611-5. PMID: 21395655
- The metabolites N-desmethylclozapine and N-desmethylolanzapine produce cross-tolerance to the discriminative stimulus of the atypical antipsychotic clozapine in C57BL/6 mice. | Wiebelhaus, JM., et al. 2011. Behav Pharmacol. 22: 458-67. PMID: 21712711
- Determination of olanzapine and N-desmethyl-olanzapine in plasma using a reversed-phase HPLC coupled with coulochemical detection: correlation of olanzapine or N-desmethyl-olanzapine concentration with metabolic parameters. | Lu, ML., et al. 2013. PLoS One. 8: e65719. PMID: 23741510
- Solid Phase Extraction Purification of Saliva Samples for Antipsychotic Drug Quantitation. | Dziurkowska, E. and Wesolowski, M. 2018. Molecules. 23: PMID: 30424479
- Obsessive-compulsive symptoms in patients with schizophrenia: Relationships with olanzapine pharmacological parameters, psychopathology, and quality of life. | Wu, TH., et al. 2019. Psychiatry Res. 276: 1-5. PMID: 30981095
- Metabolic and endocrinal effects of N-desmethyl-olanzapine in mice with obesity: Implication for olanzapine-associated metabolic changes. | Zhang, X., et al. 2019. Psychoneuroendocrinology. 108: 163-171. PMID: 31302499
- Simultaneous Quantification of Antipsychotic and Antiepileptic Drugs and Their Metabolites in Human Saliva Using UHPLC-DAD. | Dziurkowska, E. and Wesolowski, M. 2019. Molecules. 24: PMID: 31416290
- Effects of Age, Drug Dose, and Sampling Time on Salivary Levels of Olanzapine, Quetiapine, and Their Metabolites. | Dziurkowska, E. and Wesołowski, M. 2020. J Clin Med. 9: PMID: 33066306
- Entry of the antipsychotic drug, olanzapine, into the developing rat brain in mono- and combination therapies. | Huang, Y., et al. 2022. F1000Res. 11: 1417. PMID: 36798113
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
N-Demethyl Olanzapine, 100 mg | sc-208019 | 100 mg | $571.00 |